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ABSTRACT
Achondroplasia and hypochondroplasia are two forms of skeletal dysplasias caused
predominantly by single base mutations in the fibroblast growth factor receptor 3 gene
(FGFR-3).  The mutation for achondroplasia is a G1138A/C substitution and the mutation
for hypochondroplasia (occurring about 50% of the time) is a C1620A/G substitution.
Recent genetic studies have shown that spontaneous mutations for achondroplasia and
hypochondroplasia occur exclusively on the paternally derived chromosome, suggesting
that these mutations occur preferentially during spermatogenesis.  For unknown reasons,
the mutation rates at these FGFR-3 nucleotides appear to occur at a much higher frequency
than nucleotide specific mutation rates observed in other human genetic diseases.
The purpose of this study was to develop an assay that could detect the frequencies
of achondroplasia and hypochondroplasia causing mutations in human sperm.  A Needle-
in-a-Haystack PCR/RE/LCR selection technique has been developed that measures single
base changes, commonly single base substitution mutations, at sensitivities of one mutant
allele in one cell in up to 107 wild-type cells.  This technique was modified and designed
for the achondroplasia and hypochondroplasia base sites 1138 and 1620 of the FGFR-3
gene.  With the development of this technique, future studies could focus on determining
the frequencies of the mutations in the sperm of fathers of affected children and the
frequencies of the mutations in the sperm of the normal population.  These studies will
help elucidate the paternal age effect, have important implications in genetic counseling
and provide a novel method by which to study genetic disease in humans.
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CHAPTER 1.  INTRODUCTION
The fibroblast growth factors are a complex family of mammalian signaling
molecules.  Their interaction with their corresponding family of fibroblast growth factor
receptors constitutes a very dramatic cell signaling pathway responsible for many different
molecular processes.  Many human disease processes have been linked with faulty growth
factors and/or growth factor receptors.  Two such diseases, achondroplasia and
hypochondroplasia, are caused by single base mutations in the fibroblast growth factor
receptor 3 (FGFR-3) gene.
These mutations to the FGFR-3 gene result in the constitutive activation of the
receptor and its subsequent cell signaling pathway.  Through a complex series of molecular
events, the insult to FGFR-3 alters the finely tuned process of long bone growth and
development leading to varying forms of short-limb dwarfism.
The incidence of short-limb dwarfism in the population is between 1 in 15,000 and
1 in 40,000 live births.  This high degree of incidence makes the FGFR-3 gene one of the
most mutation prone genes in the human genome.  In addition to the high rate of mutation,
these mutations in an affected individual are derived from the paternal allele.  A paternal
age effect has also been shown for these mutations.
Because the achondroplasia and hypochondroplasia mutations are both derived
from the paternal allele, and because there is an increased incidence with advanced
paternal age, it is believed that germline mutations are responsible for the development of
the disease in offspring.  It is not known, however, whether these germline mutations occur
early in the development of sperm stem cells, or later in the processes of spermatogenesis.
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It is also unknown as to whether or not the mutation is found through the entire population
of stem cells, or rather, in an isolated pocket of mutated stem cells.
For these reasons, it would be very beneficial to be able to determine the frequency
of the achondroplasia and hypochondroplasia causing mutations in a population of human
sperm.  The ability to compare these frequencies in the sperm of males with affected
offspring, to affected males, and to normal individuals would be very beneficial in
determining the origin and effects of these germline mutations.
This project focused on creating an approach to measuring the frequency of
achondroplasia and hypochondroplasia causing FGFR-3 mutations in human sperm.  This
would be accomplished by designing a highly sensitive assay that could detect one mutated
genome in a background population of one million wild-type cells.  In future endeavors,
this assay could then be used to measure the frequency of the mutations in the sperm of
fathers with affected offspring, affected individuals, and normal males.
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CHAPTER 2.  FIBROBLAST GROWTH FACTORS
The fibroblast growth factors are a family of structurally related proteins that are
responsible for a wide array of control and signaling in many biological systems.  To date,
over twenty different types of fibroblast growth factors (FGFs) have been discovered,
called FGF-1 to FGF-23.  All of these proteins have been defined as FGFs because of two
characteristics.  The first is that they all contain a central core of 140 amino acids that are
highly homologous throughout the classes of these FGF proteins.  This core forms twelve
antiparallel β-strands that together construct a cylindrical barrel that is enclosed by the
variable region of the growth factors.  The second characteristic is that they all have a high
binding affinity for heparin and heparin-like glycosaminoglycans (HLGAGs) (Ago et al.
1991, Zhang et al. 1991).  These are the defining features that place a polypeptide in the
FGF family, not specificity of growth promoting activity.  In fact, some FGFs do not
stimulate fibroblasts at all.  Therefore, these factors are given the name FGF family based
on structure, not function (Baird and Klagsbrun 1991).
FGFs are produced in almost every cell of the body.  The amount of the respective
FGF depends on the time of development and what organ is being examined.  For instance,
FGF-3 is produced primarily during early embryonic development while FGF-9 was
isolated from mature glial cell lines (Basilico and Moscatelli 1992, Miyamoto et al. 1993).
After the FGFs are produced, they are secreted from the cells into the extracellular
matrix (ECM) by one of two mechanisms.  Most FGFs use the classic endopasmic
reticulum-Golgi body pathway of secretion.  FGFs-1, -2, and -9 use an as of yet undefined
endoplasmic reticulum-Golgi body independent pathway.  In the ECM, the factors bind the
heparin molecules and serve as a spatially regulated reservoir outside of the cells.  The
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polypeptide can then either remain in the ECM to act on cells in close proximity, or it can
be digested from the matrix and bind to a FGF binding protein and be carried away from
its immediate environment to act on more remote cells (Folkman et al. 1988).
The functions of the FGFs are almost as variable as the number of different growth
factors.  FGFs have demonstrated the ability to be potent mitogens in vitro for cells of
mesodermal, ectodermal, and neuroectodermal origin.  In addition to the FGFs’
proliferative nature in vitro, FGFs can also modify a target cell’s motility, differentiation,
extension of neuritis, and survival.  These molecules have also been implicated in vivo in
serving as major components of such processes as embryonic and fetal development,
neovascularization, and response to healing.  Regulation of growth by FGFs is aided by the
nature of the protein in the ECM.  When the FGFs are bound to heparin molecules that are
confined to the ECM, only the cells in direct contact with the ECM can be targeted.  This
is very important in regulating the growth of developing limbs in the embryo as well as
new vascularization and tissue proliferation throughout life.  As a result of the importance
of FGFs in new tissue formation, some FGFs have also been implicated to play a role in
tumor growth and development (Powers et al. 2000).
The large number of different types of FGFs and the wide range of their functions
demand a complex signaling system.  The role of the FGF is carried out by its binding to
the fibroblast growth factor receptor (FGFR).
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CHAPTER 3.  FIBROBLAST GROWTH FACTOR RECEPTORS
The important relationship between FGFs and fibroblast growth factor receptors
(FGFRs) has been a major focus of study for the past decade.  Moscatelli initiated the
belief that fibroblast receptors existed in 1987.  By using radiolabeled FGF-2, he found
that the protein bound with high affinity to a protein on the surface of baby hamster kidney
(BHK) cells.  Studies then determined that these FGFs were binding to a high affinity site
of a protein that was between 125 and 160 kDa (Blanquet et al. 1989).
The first breakthrough to as to the overall structure of the FGFR protein occurred in
1989.  The proteins at the high affinity binding sites were isolated from chicken embryos
and their amino acid sequence was determined.  Using oligonucleotide probes based on
this protein sequence, the receptor cDNA was cloned. (Lee et al. 1989)  The first FGF
receptor was found to be a single unit transmembrane protein made up of three parts. The
first part is an extracellular region containing three extracellular immunoglobulin-like
domains, which is the ligand-binding domain of the receptor.  The immunoglobulin-like
domains were named IgI, IgII, and IgIII.  It was also discovered that there was an acidic
region between IgI and IgII.  The second region was a transmembrane domain.  The third
region was an intracellular unit that consisted of a tyrosine kinase domain (Figure 1.).
The discovery of the intracellular tyrosine kinase domain reinforced earlier studies
by Coughlin et al. (1988) as to the mechanism of the FGF receptor.  In these studies, they
showed that FGF-1 and FGF-2 stimulated tyrosine phosphorylation in certain strains of
fibroblast cells by using phosphotyrosine antibodies and Western blot staining.  These
techniques were used to define the first two FGF receptors named FGFR-1 and FGFR-2.
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Figure 1.  Schematic representation of the FGFR-3 protein. (Modified from Spivak-
Kroizman et al. 1994)
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To date there are four FGFRs that are now defined and characterized.  The four
share between 55% and 72% homology at the protein level. (Johnson and Williams 1993)
It has also been shown, however, that receptor diversity plays a major role in defining the
function of the FGF-FGFR signaling system.  The multiple types of FGFs and their wide
range effects on target cells demands a diverse system of receptors.  For example, FGF-7
elicits a mitogenic response in keratinocytes but not fibroblasts or endothelial cells
(Rubinet al. 1989).  This led to the belief that the FGF-FGFR signaling system differs
between the cell types.
In order to gain the diversity in these cells, as well as other cells expressing FGFRs,
it is believed that the receptors use one of two mechanisms, either alternate splicing of the
same gene, or analogous splice variants of different genes.  In either case, most of these
variances occur in the immunoglobulin-like domains or in the tyrosine kinase domains
(Johnson and Williams 1993).  For instance, FGFR-1 has three possible ends to the IgIII
region named IIIa, IIIb, and IIIc.  These different ends to the third immunoglobulin-like
domain allow the receptor to change its specificity for different FGFs.
Because of the large number of FGFs and the different forms of the FGFRs, there
are still many questions as to the exact processes of interaction between the two and how
they all interact with each other.  It is known, however, that the great diversity in the signal
and receptor process is accomplished by different FGFs binding to different FGFR splice
variants and different fgfr gene products.
The FGF receptor behaves like most other tyrosine kinase receptors to initiate a
signal transduction pathway.  Binding of FGFs to the extracellular domain of the receptor
turns on the catalytic activity of the tyrosine kinase domain on the cytosolic side of the
receptor.  This is accomplished by FGFR dimerization.  When a FGFR receptor is bound
8
by a FGF, it dimerizes with another FGFR-FGF complex (Plotnikov et al. 1999).  The
catalytic domain of one receptor complex phosphorylates tyrosine residues on its own
catalytic domain and the catalytic domain of the adjacent receptor complex and vice versa
(Lemmon and Schlessinger 1994).  Autophosphorylation gives the receptor a greater
capacity to phosphorylate other targets within the cell.  The dimer may consist of FGFRs
of the same type, i.e. FGFR1-FGFR1, or the dimer may consist of two different receptors
in the same family, i.e. FGFR1-FGFR2 (Bellot et al. 1991).  This added variance to
receptor function contributes to the wide spectrum of FGF signaling. (Figure 2.)
After the FGFR receptor has become activated, the tyrosine kinase begins
activating proteins of the signal cascade by phosphorylation.  The most common sites of
phosphorylation are Src-homology-2 (SH2) regions on target proteins.  Phosphorylation of
the target protein usually causes a conformational change that activates various catalytic
activities unique to the target.  FGF receptors generally activate four different protein
pathways to propagate the signal.  The first is phosphorylation of the SH2 domain of
phospholipase C-gamma (PLCγ) to stimulate activation.  Activated PLCγ then goes on to
cleave phosphatidyl-inositol-4,5-bisphosphate to inositol triphosphate (IP3) and
diacylglycerol (DAG).  IP3  is then responsible for releasing calcium stores within the cell
while DAG and calcium activate protein kinase C, a second messenger protein.  The
second pathway is to phosphorylate the SH2 domain of the protein Crk which in turn
activates other signaling molecules Shc, Cas, and C3G.  Crk is an SH2/SH3- containing
adaptor protein which helps to link FGFR to other downstream signaling molecules
(Larsson et al. 1999).  Shc helps to link FGF receptors to the Ras signaling pathway
(Yulug et al. 1995).  The Cas (cellular apoptosis susceptibility) protein is believed to
function in mammalian cells in both apoptosis and cell proliferation (Brinkmann
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Figure 2.  Schematic representation of a dimerized FGFR-3 complex and the
phosphorylization of signaling complexes that lead to the activation of the Ras system.
10
 et al. 1996).  C3G (guanine nucleotide-releasing protein) is also believed to help
transducer signals from tyrosine kinases to the Ras system (Tanaka et al. 1994).  The third
protein activated using SH2 is the Src protein, which is a membrane bound, non-receptor
tyrosine kinase.  The Src protein is believed to amplify the original signal.  The fourth
protein system, the SNT-1/FRS-2 protein is unique in that it does not use SH2.  Two
independent groups discovered this protein by using mutated FGFRs that did not contain
any catalytic tyrosine residues.  They found that the FGFR still phosphorylated the SNT-
1/FRS-2 protein.  This protein, through a series of events, is believed to recruit the Ras
protein (Wang et al. 1996, Kouhara et al. 1997).  The subject of the FGFRs’ signaling
system is still largely unknown.  The various combinations of FGFs and FGFRs contribute
to the complexity of the system and there is a seemingly endless outcome to each signal.
This signaling pathway is heavily dependent on heparin, as mentioned above.
Heparin in the pericellular matrix or in transmembrane proteoglycans associates with FGFs
and the extracellular surface of the FGFRs, allowing the FGFR signaling complex to
recognize changes in its immediate environment (McKeehan et al. 1984).  These changes
add to the great diversity of the complex signaling system, and heparin is believed to aid in
keeping everything organized.  Heparan sulfate has also been implicated in many aspects
of FGF stability, receptor stability, FGF-FGFR complexes, receptor function, and non-
signal stability of the FGF receptor (Luo et al. 1996, Kato et al. 1998, Moy et al. 1997).
Heparan is believed to have two major roles in receptor function. The first is to help
maintain a general stability over the entire system by divalent cation-dependent high
affinity interaction with the FGFRs that help ensure proper binding with FGFs (Kan et al.
1996).  The second is to inhibit random receptor dimerization in the absence of FGF.  This
is achieved because of HLGAGs’ (heparin-like glycosaminoglycans) ability to bind to a
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specific site on the FGFR protein.  This site lies between two immunoglobulin-like
domains that when HLGAGs are not bound, tend to favor non-signal dimerization.  FGF
binding removes the HLGAGs then allowing receptor dimerization (Kan et al. 1996).
12
CHAPTER 4.  FIBROBLAST GROWTH FACTOR RECEPTOR 3
In 1991, Keegan et al., isolated a new human tyrosine kinase receptor cDNA.  This
cDNA was highly homologous to the previously described FGFRs.  This receptor was a
125-kDa glycoprotein that, through calcium efflux studies, was shown to be activated by
human FGF-1 and FGF-2.  Because of the common attributes shared between this ‘new’
receptor and the other FGFRs, it was given the name FGFR-3.  FGFR-3 is made up of
three immunoglobulin-like regions, a transmembrane domain, and a cytoplasmic tyrosine
kinase receptor.  The IgI and IgII domains are separated by an acidic amino acid sequence
and the tyrosine kinase domain is split into two parts by a series of 14 amino acids
(Figure1.)(Keegan et al. 1991).
Thompson et al. (1991) isolated the FGFR-3 gene from the Huntington’s Disease
(HD) region of chromosome 4, p16.3, an area spanning about 2.5 million base pairs.
Initial research into the FGFR-3 gene was hoping to point to its site as a possible candidate
for the HD gene because of its involvement with growth factors and its map location.
This, however, did not prove to be the case.
The FGFR-3 gene contains 19 exons and 18 introns spanning 16.5 kilobases
(Perez-Castro et al. 1997).  The cDNA consists of 4.4 kb and contains an open reading
frame of 2,520 nucleotides.  The FGFR-3 protein is made up of 840 amino acids.
FGFR-3 expression is highest during early embryonic development.  Most of the
activity is seen in the precartilagenous condensing mesenchyme and in bony and
cartilagenous structures of the developing vertebrate (Peters et al. 1993).  Further on in
development it is concentrated in the perichondrium, the resting cartilage, and the
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maturation and hypertrophic zones of the growth plate.  Here it is believed to play a major
role in chondrocyte differentiation.
There are two different isoforms of the FGFR-3 receptors, depending on splice
patterns.  These two isoforms differ in which third immunoglobulin-like domain is used
and are so named FGFR-3 IIIc and FGFR-3 IIIb.  The IIIb form was isolated from
epidermal keratinocyte cell populations in the mouse skin.  The IIIc form was found in
nonepithelial cell populations predominantly the brain, spinal cord, and other bony
structures in the mouse (Murgue et al. 1994, Keegan et al. 1991).  These splice forms not
only differ in the tissue in which they are expressed, but also their ligand affinity and
preferential ligand binding.
FGFR-3 has been shown to be activated by FGF-1,-2,-4,-8, and –9 (Vajo et al.
2000).  The variability of FGFR-3 receptor itself and the number of FGFs that may activate
the receptor give the system a high range of possible signals.
Like the other FGFRs, an enormous cascade of events takes place after a ligand has
bound to the FGFR-3 receptor.  For the most part there are great similarities in all the
signaling systems. FGFR-3 primarily links itself to the Ras/MAPK system through a
unique interaction between GRB2-nucleotide exchange factor Sos complex and either the
Shc protein or the 80K-H protein (Figure 2.)(Kanai et al. 1997). This system has been
implicated as a signaling pathway important for growth factor induced cell cycle
progression.
Disruption of the FGFR-3 gene in mice was initiated in order to study the specific
function of the signaling system.  Mice with homozygous disruptions of the FGFR-3
receptor showed enhanced growth of long bones and vertebrate.  This suggests that the
FGFR-3 gene negatively regulates bone growth (Deng et al. 1996, Colvin et al. 1996).
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Fibroblast growth factor receptor 3 (FGFR-3) is perhaps the most well know of the
other fibroblast growth factor receptor proteins.  Defects in this gene cause a myriad of
skeletal dysplasias, i.e. achondroplasia, hypochondroplasia, thanatophoric dysplasia,
Crouzon syndrome, Muenke syndrome, and SADDAN dysplasia.  The two most common
defects, achondroplasia and hypochondroplasia, are the focus of this study.
15
CHAPTER 5.  SKELETAL DYSPLASIAS
5.1 ACHONDROPLASIA
Achondroplasia (ACH) is the most common genetic form of short-limb dwarfism.
It is an autosomal dominant trait and occurs between 1 in 15,000 and 1 in 40,000 live
births (Jones et al. 1988, Gorlin et al. 1990, Murdoch et al. 1970, Gardner et al. 1977,
Oberklaid et al. 1979, Andersen and Hauge 1989, Stoll et al. 1989).  There are many
phenotypic characteristics of ACH.  These include a host of skeletal abnormalities
including, but not limited to, rhizomelic dwarfism, relative macrocephaly, exaggerated
lumbar lordosis, characteristic facies with frontal bossing and mid-face hypoplasia,
limitation of elbow extension, genu varum, trident hand, hyperextension of most joints,
and other typical bone abnormalities (Jones et al. 1988).  These characteristics contribute
to varying expressions of the disease Achondroplasia.  An affected individual may have a
small or high number of these discernable characteristics.  However, these characteristics
are obvious and consistent enough to ensure proper clinical diagnoses based on physical
observation and radiological techniques at the time of birth.
Histologically, achondroplasia affected individuals show a defect in chondrocyte
function during endochondral bone formation.  Chondrocytes in the maturing growth plate,
specifically the hypertrophic zone, appear to be inhibited during their maturation and
development and the frame for matrix calcification is never properly constructed.  This
severely compromises the length of long bones in the mature individual (Ponseti et al.
1970).
In 1994, the gene responsible for causing achondroplasia was mapped by two
groups to the distal 2.5-Mb region of chromosome 4. One group accomplished this by
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studying 14 pedigrees while the other used 18 multigenerational families with
achondroplasia and 10 short tandem repeat polymorphic markers from this region (Velinov
et al. 1994, Francomano et al. 1994).  In the same year, the gene causing
hypochondroplasia (HCH) was also linked to the short arm of chromosome 4.  This study
also determined ACH and HCH genetically related (LeMerrer et al. 1994).
These studies pointed to a number of possible genes that might be responsible for
ACH.  The candidates for the disease included the FGFR-3 gene and because of its known
function as a mitogenic receptor, efforts were concentrated on this site.  Within six months
of mapping the disease to this region of the chromosome, characteristic mutations were
documented.
Shiang et al. (1994) and Rousseau et al. (1994) screened the gene for mutations in
achondroplastic probands and found a common mutation in the transmembrane coding
domain of the gene.  In 15 of 16 affected individuals, Shiang found that there was the same
G-to-A transition at nucleotide 1138.  The mutation of the other individual who did not
have the G-to-A transition had a G-to-C transversion at the same nucleotide (Shiang et al.
1994).  Both mutations lead to a substitution of an arginine residue for a glycine residue
(gly380arg or G380R) at position 380 of the final protein.  Concurrently, Rousseau found
the same G380R mutation in all cases studied which included 17 sporadic cases and 6
unrelated familial cases (Rousseau et al. 1994).
In a larger study in 1995, Bellus et al. found the G-to-A transition in 150 of 154
unrelated achondroplasia affected individuals, the G-to-C transversion in 3 affected
individuals, and in an atypical case an affected individual with out either mutation (Bellus
et al. 1995).  Additional studies in Sweden, Japan, and China have reported the same
G380R mutation (Ikegawa et al. 1995, Alderborn et al. 1996, Wang et al. 1996).  Because
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of the relatively high occurrence of achondroplasia in the population and the consistency of
the mutation, nucleotide 1138 is considered the most mutable nucleotide in the human
genome.
The result of a transmembrane mutation in the FGFR-3 has been a vast area of
study over the last decade.  Previous studies involving mice with disrupted FGFR-3 genes
showed that the absence of a properly functioning gene product leads to long bone and
vertebrate overgrowth.  It could then be inferred that the FGFR-3 receptor is responsible
for containing/controlling long bone growth.  Because ACH individuals typically have
stunted long bone growth and short stature, it can be concluded that the G380R mutation in
the transmembrane domain might produce an overly active FGFR-3 receptor, with a gain
of function nature that is ligand independent.
This general theory has proved to be the case except for a few minor exceptions.
Substitution of a glycine for an arginine in the transmembrane domain of FGFR-3 results
in the stabilization and accumulation of mutant receptor at the cell surface.  The result is a
prolonged period of ligand activated receptor signaling (Monsonego-Ornan et al. 2000).
The ligand is needed for over activation of the receptor in achondroplasia but as will be
seen later this is not the case for other skeletal dysplasias.  Growth is stunted because the
extended length of inhibition at the growth plates of long bones slows chondrocyte
terminal differentiation.
The process of long bone growth is a highly sensitive series of events that are
dependent on coordination and precise balance among chondrocyte proliferation,
differentiation, cartilage matrix formation, and mineralization within the growth plate.
These events are under a great deal of influence from local and distant signals, such as
hormones and fibroblast growth factors.  The timing and concentration of these signals are
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critical during development.  Because of the highly tuned series of event that take place at
the growth plate, it becomes very sensitive to even the smallest insults, such as an altered
FGFR-3 receptor.        
5.2  HYPOCHONDROPLASIA
Hypochondroplasia (HCH) is another genetic disorder of short stature.  It was
initially described in 1913 but wasn’t officially termed and recognized until 1960
(Ravenna et al. 1913, Maroteaux and Lamy 1964).  It is very similar to achondroplasia but
has a less severe phenotype.  General characteristics of HCH share those of ACH and
include, but are not limited to, rhizomelic shortening of the limbs, short fingers,
megalocephaly, narrowing of the spinal cord, square and shortened ilia, and shortened
tubular bones (Walker et al. 1971).  These features do tend to be much milder than those of
ACH, though.  Hypochondroplasia has a wide range of possible phenotypes, and unlike
achondroplasia, the clinical diagnoses and radiological findings may be somewhat vague in
pointing to the disease.  Hypochondroplasia is therefore addressed on a case by case basis.
There has been established, however, a discernable difference between achondroplasia and
hypochonroplasia from both clinical and radiological diagnoses.  Hypochondroplasia is an
autosomal dominant mutation (Beals et al. 1969).  It is not as common as ACH, but its rate
of occurrence has not yet been calculated.  This is due in part to the wide range of
phenotypes and the fact that childhood onset of symptoms occurs regularly.
It was theorized that achondroplasia and hypochondroplasia are allelic based on the
similarities in phenotype of the two disorders and the identification of a severely dwarfed
individual whose father had achondroplasia and whose mother had hypochondroplasia
(McKusick et al. 1973).  The discovery of the common G1138A/C mutation in the FGFR-3
gene in ACH individuals also encouraged the search for hypochondroplasia to the same
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gene.  In 1995, Bellus and Prinos located a common mutation in exon 13 of the FGFR-3
gene in HCH individuals.  They both discovered an asparginine to lysine substitution at
amino acid 540 (asn540lys or N540K) in the final protein (Bellus et al. 1995, Prinos et al.
1995).  There was some contradiction in the exact nucleotide number however, Bellus
called it a C1620A/G mutation while Prinos, using a different numbering system, called it
a C1659A/G mutation.  Today it is numbered base 1620.  They both mapped it to amino
acid 540, though, which is located in the proximal tyrosine kinase domain of the final
protein.
ACH and HCH have been separated genetically and there appears to be no
crossover of mutations between the diseases.  In 1995, Stoilov et al. found the gly380arg
mutation in 21 of 23 ACH individuals while the same mutation was not found in any of the
8 HCH individual studied (Stoilov et al. 1995).
The percentage of individuals with this mutation wasn’t as high as the 95% of ACH
individuals who had the G1138A/C gly380arg substitution.  These percentages fell more
on the order of about 50% to 70%.  Bellus et al. found the C to A mutation in 8 of 14
(57%) individuals and Ramaswami et al. found the same mutation in 28 out of 65 (43%)
individuals with hypochondroplasia (Ramaswami et al. 1998).  Also in 1998, Fofanova et
al. studied 16 individuals and found that 6 had the C to A mutation and 3 had the C to G
mutation (56% at nucleotide 1620) (Fofanova et al. 1998).  In a study of 18 Taiwanese
patients, Tsai et al. found the C to A mutation in 6 patients and the C to G mutation in 4
patients (56% at nucleotide 1620) (Tsai et al. 1999).
Because the C1620A/G mutation did not account for all of the HCH individuals,
the FGFR-3 gene was screened for other mutated sites.  Novel mutations were found in the
FGFR-3 gene of HCH individuals such as ile538val, ans540thr, asn328ile, lys650asn/gln,
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and asn540ser (Grigelionene et al. 1998, Deutz-Terlouw et al. 1998, Winterpacht et al.
2000, Bellus et al. 2000, and Mortier et al. 2000).  These additional mutations have helped
to account for most of the mutations in HCH affected individuals, however, there have still
been a few HCH individuals who have not had any of these mutations.  Overall, this leaves
HCH individuals broken into two categories, those with FGFR-3 mutation and those
without.  A great deal of study has also gone into determining whether or not different
mutations may lead to different phenotypes, but this had been a rather daunting
undertaking.
Hypochondroplasia has been termed a genetically heterogeneous disease.  This is
due to the fact that not all of the individuals with the disease carry the same mutation.
Because the HCH N540K mutation lies in the proximal tyrosine kinase domain of
the FGFR-3 receptor, it results in functional problems unlike those of mutations in the
transmembrane domain.  As mentioned previously, transmembrane mutations cause the
FGFR-3 receptor to harbor an extended response in the presence of FGF ligands.  The
tyrosine kinase mutation, however, causes a ligand independent activation of the receptor.
The receptor may also become activated without dimerization.  A major difference
between the two mutations though, is that when a FGF ligand does bind to the receptor, a
great deal of wild type FGFR-3 function ensues, thereby possibly negating the mutation
(Raffioni et al. 1998).  The return of some wild type function may account for the less
severe and noticeable phenotype of hypochondroplastic individuals.
Hypochondroplasia presents a wide spectrum of developmental irregularities and
skeletal abnormalities.  There have been dozens of clinical cases to date of the varying
phenotypic degrees of the disease and the mutations that may cause them.  The many
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different mutations of the receptor and the consequences of the mutations on function are
beyond the scope of this thesis.
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CHAPTER 6.  MUTATIONS AND DISEASE
Advances in molecular genetics over the last two decades have increased our
understanding of the origins of genetic mutations.  The bulk of these studies, though, have
focused on prokaryotic and lesser eukaryotic organisms, such as the fruit fly Drosophila
melanogaster.  However, little has been discovered on the processes of mutation in the
human genome.  Research has been able to point to mutations causing many genetic
diseases, but the actual origin and processes behind these disease causing mutations has yet
to be discovered.  Achondroplasia and Hypochondroplasia are both genetic diseases whose
mutation site is known but the origin of the mutation remains a mystery.
There are many factors that are believed to contribute to the process of mutation.
These can be classified as either exogenous or endogenous processes.  Exposure to
radiation and chemicals that permanently alter the DNA are the two most widely accepted
processes for exogenous mutation induction.  However, there are mutations that can occur
without exposure to harmful radiation or mutagenic chemicals.  These endogenous
mutations can occur because of an error in proofreading during replication or from a
spontaneous occurrence like spontaneous deamination of 5-methylcytosine.  These types of
mutations can also be referred to as ‘spontaneous mutations’.  Generally, a spontaneous
mutation has come to mean a phenotypic mutation in an offspring that is not evident, at
least phenotypically, in the paternal genome.
Spontaneous mutation is generally considered to be harmful to an individual and
have deleterious effects.  However, mutation is thought to be very beneficial on an
evolutionary level and the driving force behind natural selection.  Therefore, it would be
23
advantageous to be able to estimate the rate of spontaneous mutation in the human
genome.  This would provide some preliminary clues as to the rate of evolution.
Many attempts have been made to correctly calculate the rate of spontaneous
mutation in the genomes of many different species.  It was discovered that the rates of
spontaneous mutation per genome are remarkably similar within broad groups of
organisms, but differ greatly among groups.  Mutation rates in RNA viruses that contain at
least 104 bases is about 1 mutation per genome per replication for lytic viruses and about
0.1 mutation per genome per replication for retroviruses.  The mutation rate for microbial
organisms with DNA based genomes is on the rate of about 1/300 per genome per
replication.  Mutations in higher eukaryotes have a much broader range, something on the
scale of 0.1-100 per genome per sexual generation or per meiotic event (Drake et al. 1998).
The difficulty in understanding the comparison between the different groups of
organisms stems from the methods of studying the mutations and the total amount of
essential DNA in the organism’s genome.  Viruses have relatively small genomes when
compared to eukaryotes and the bulk of their DNA is essential for proper function and
survival of the organism.  Studies also measure the rate of mutation based on a rate of
phenotypic change.  Therefore, a mutation of the virus’ DNA in an essential portion of the
genome is much more phenotypically relevant than a mutation in the eukaryotic genome in
a nonessential region.  This fact is one of the major reasons that it has been difficult to
accurately extrapolate human spontaneous mutation rates based on studies of lower
organisms.
The genetic diseases achondroplasia and hypochondroplasia provide good models
by which to study spontaneous mutation.  The human genome is relatively large and
complex.  It contains a relatively small portion of meaningful genetic code.  Because of
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this it can be assumed that most spontaneous mutations, like single base substitutions, do
not result in any phenotypic change.  The use of the third base ‘wobble’ in each codon, in
which the third base doesn’t account for much difference between amino acids, also helps
to mask spontaneous mutations in the human genome. Mutations resulting in amino acid
changes in nonessential regions of the protein product may also go unnoticed.  Therefore,
dominant mutations, especially those with complete penetrance and dramatic phenotypes,
like achondroplasia and hypochondroplasia, have served as the main means to study
spontaneous mutation in man during this century.
Although the frequency of spontaneous mutations is quite important in
understanding the origin of genetic diseases, the cell type and stage of that cell in its
development is another significant factor to consider.  If a spontaneous mutation occurs in
a cell, it is usually not a significant event until that cell has clonally expanded or given rise
to the next generation of a germ cell. The function and importance of the cell is also a
major consideration.  Somatic cells with mutations can go largely unnoticed.  Problems
arise most often when the mutation confers a replicative advantage to a group of cell, as
such is the case with general tumor formation.  Germ cells, however, with mutation can
pass the mutation on to future offspring.  This notion is particularly significant in the male
germ cell.  A germ cell with a mutation can undergo spermatogenesis and develop into
sperm carrying the mutation.  More importantly the germ cell can undergo mitosis and
clonally expand the mutation among the entire population of germ cells to the point where
the majority of sperm produced all carry the same mutation.
As mentioned previously, the deamination of 5-methylcytosine in a germ cell is a
process by which a spontaneous point mutation can occur.  One of the areas where
spontaneous deamination of 5-methylcytosine occurs most frequently in the genome is at
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cytosine-guanine (CpG) dinucleotides (Bird 1980).  CpG sites are most affected because
these cytosine nucleotides, bonded with guanine, have the highest proportion of
methylation among the cytosine nucleotides.
Cytosine methylation is a very important signal in normal cellular function.
Methylation of various base pairs at these sites helps to create developmental signals on
the genome for different enzymes that are active during embryogenesis.  Methylation is
believed to either turn ‘on’ or ‘off’ different genes during development.  Methylation is
also used as an epigenetic modification marker of parental imprinted genes (Bird 1987).
Deamination of 5-methylcytosine at CpG sites is considered to be one of the major
endogenous mechanisms for the induction of spontaneous mutations.  Deamination of 5-
methylcytosine forms thymidine and generates a G-T mismatch which, if not repaired,
produces a C to T transition.  Deamination of cytosine can also generate a C to T transition
if uracil glycosylase and G-T mismatch repair are inefficient.
Because 5-methylcytosines are so easily mutated, molecular studies of the genome
have shown that they are severely underrepresented.  They probably are actually
represented by a factor of 4 to 5 more than found in the genome (Schorderet and Gartler
1992).  This leaves the remaining 5-methylcytosines with an even larger impact on the
spontaneous mutation in the human genome.  Studies have shown that approximately 37%
of all spontaneous germ-line mutations responsible for genetic disease are localized to
CpG dinucleotides (Cooper and Youssoufian 1988).
Deamination of 5-methylcytosine appears to be a major factor in the formation of
achondroplasia mutations.  In almost all cases of achondroplasia, the mutations were
spontaneous mutations from glycine to arginine at base site 1138.  This guanine is part of a
CpG dinucleotide.
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It has been accepted for quite some time now that the distribution of the parental
origin of germ-line mutation is not equally distributed between the sexes.  This became
evident in the first studies on hemophilia.  Haldane et al. (1947) first reported that there
was a higher male than female rate for the origin of mutation in hemophilia families.
Lately, molecular genetics has confirmed a sex bias in germ-line mutations.  Most studies
of the sex ratio for point mutations in hemophilia A and B have shown a greater number of
mutations in males (Rosendaal et al. 1990, Sommer and Ketterling 1996).  This effect is
even more pronounced with respect to point mutations leading to hemophilia at CpG sites,
which account for about 40% of all point mutations in hemophilia.
There are three major explanations for the observed sex bias in the origin of
spontaneous mutation.  The first theory is that if germ-line mutations are assumed to be
largely the results of replication errors, then the higher number of mitotic cell divisions in
the development of spermatocytes, relative to oocytes, might explain the higher mutability
of spermatocytes (Vogel and Motulsky 1997).  In females, there are 22 cell divisions
before meiosis and two during meiosis, giving 23 chromosome replications in total,
because only one replication occurs during two meiotic divisions.  The sperm produced by
a 40 year old man, however, has gone through 610/23, or more than 25 times as many
chromosome replications as an egg (Crow 2000).
A second theory is that there is a difference in the levels of CpG methylation
between males and females that might result in sex-specific mutation patterns, particularly
a higher rate of mutation among males compared to females (Driscol and Migeon 1990,
Crow 1997).  However, studies have shown that while DNA methylation is a major
determining factor for recurrent CpG germ-line mutations in individuals with hemophilia
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and achondroplasia, the higher mutation rate in the male germ line is apparently not a
simple reflection of sex-specific methylation differences (El-Maarri et al. 1998).
The third theory behind an increase in germ-line spontaneous mutations is that
there might be a combination of both mechanisms.  This would mean that there is a
fixation of mutation at 5-methylated CpGs as a result of the increased number of male
chromosome replications.
It has been accepted for quite some time now that older parents are at more of a risk
of having children with genetic disorders.  A great deal of work has gone into studying the
changes of reproductive functions, fertility, and genetic risks of ageing women.  The best
known example of a direct maternal age effect occurs in Down syndrome.  This disease
occurs as a result of transmission of an extra chromosome 21 at the first meiotic division of
the oocyte.  Transmission of an extra chromosome, also known as trisomy, is much more
common in older age females than males (Hassold 1996).  It is estimated that about 0.3%
of liveborns have an abnormal number of chromosomes, with the most dominant one being
chromosome 21.  For trisomy 21, almost all extra chromosomes were of maternal origin.
The nondisjunction process leading to an extra chromosome 21 is still largely a mystery,
though.  With males, trisomies could be easily explained by the larger numbers of
replication that each germ cell must go through during spermatogenesis.  In females,
however, there is no increase in the number of pre-meiotic cell divisions with maternal age.
As all the oocyte cell divisions are completed before birth, there is no increase in divisions
with postnatal age as with males.  One of the proposed reasons for the trisomy is perhaps
the increased amount of time the chromosomes are in suspended meiosis during the life of
the female.
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In contrast to older females, who show a higher amount of chromosome
segregation mutations, older males have been shown to have an increased incidence of
dominant genetic disorders that result from single point mutations (Vogel and Rathenberg
1975, Risch et al. 1987).  Although the number of replications a male germ cell makes
during spermatogenesis is an important consideration for the explanation of the paternal
age effect, it is probably not all inclusive.  If accumulation of mitotic errors was the sole
reason for the increased incidence of dominant disorders with advanced paternal age, one
would expect a linear increase in the incidence with age.  Instead, an exponential increase
is observed (Vogel and Rathenberg 1975, Orioliet al. 1995, Crow 1997).
Recent molecular studies have shown that mutations responsible for large numbers
of sporadic cases of MEN-2B, Apert syndrome, achondroplasia, Crouzon syndrome and
Pfeiffer syndrome occur exclusively on the paternal allele (Carlson 1994, Moloney et al.
1996, Wilkin et al. 1998, Glasser et al. 2000).  These diseases are all caused by mutations
to genes that code for receptor tyrosine kinase.  Specifically, they are recurrent point
mutations that cause various amino acid substitutions.
The FGFR-3 gene is especially unique in that is has 7 distinct genetic disorders
associated with specific missense mutations occurring in different receptor tyrosine kinase
domains (Table 1.) (Figure 3.).  The combined incidence of achondroplasia and these 6
other FGFR-3 related disorders is greater than 1 per 10,000 pregnancies.  This study
focused on two specific point mutations in the FGFR-3 gene which cause Achondroplasia
and Hypochondroplasia (Figure 4.).
Because of the large numbers of genetic diseases in the population occur at the
FGFR-3 gene, it makes our understanding of the mechanisms behind the origin of these
mutations very important.  Since it is known that the majority of the mutations behind
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achondroplasia and hypochondroplasia originate from spontaneous mutations at the
paternal allele, understanding the mechanisms behind germline mutations during
spermatogenesis would also be very beneficial.
Table 1.  FGFR-3 Missense mutations diseases and the base sites at which they occur and
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dysplaisia, Type II
K650E (A1948G) Tavormina et al. 1995
SADDAN
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P250R (C749G) Bellus et al. 1996
Crouzono-dermo-
skeletal syndrome
A391E (C1172A) Meyers et al. 1996
The objectives of this study were to determine the frequency of achondroplasia and
hypochondroplasia causing mutations in samples of human sperm.  This would be
accomplished by developing an assay that gives the frequency of the base substitution
mutations at the two most common sites for achondroplasia and hypochondroplasia, sites
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Figure 3.  Schematic representation of the FGFR-3 protein and its associated mutations and
diseases.  TDI, thanatophoric dysplasia type I; ACH, achondroplasia; AN, acanthosis
nigricans; HCH, hypochondroplasia; TDII, thanatophoric dysplaisa type II; SADDAN,
severe achondroplasia with developmental delay and acanthosis nigricans.  (Adapted from
Vajo et al. 2000)
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Figure 4.  Graphic representation of ACH and HCH mutations.  A) Positions of
achondroplasia (s1138) and hypochondroplasia (s1620) mutations in the FGFR-3 gene.  B)
Sequence of nucleotides at the mutation site.
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1138 and 1620, respectively.  Sperm samples from affected individuals, fathers of affected
individuals and normal individuals could then be assayed to determine if the frequency of
mutation is higher in any one group.
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CHAPTER 7.  APPROACH
The purpose of this study was to determine the nature of the spontaneous FGFR-3
mutations that cause Achondroplasia and Hypochondroplasia.  This would be
accomplished by determining the frequencies of these mutations in sperm samples.  With
this information, the mechanisms underlying the germline mutations and the possible
genetic origin of these diseases may be determined.  The hypothesis was that certain gene
sequences in the FGFR-3 gene are spermatogenic hotspots for viable disease causing
mutations.  It was also believed that although the frequency of the mutations might vary, it
will still increase with age.
Because both Achondroplasia and Hypochondroplasia are diseases that occur as a
result of a single base mutation in the FGFR-3 gene in a single sperm cell, a highly
sensitive assay was required to locate the mutation in a large population of sperm cells.
For this reason, the Needle-in-a-haystack, polymerase chain reaction/ restriction
endonuclease/ ligase chain reaction (PCR/RE/LCR) method of detecting rare mutations
was employed (Wilson et al. 1999).  This method is based on a selection process that
enables a significant increase in the ratio of mutant sequences to wild type sequences.  This
method has been able to detect single base changes, commonly single base substitution
mutations, at a sensitivity of one mutant allele in one cell in up to 107 wild type cells.
These Needle-in-a-haystack PCR/RE/LCR mutation detection and identification
techniques have enabled the determination of single base changes and the frequencies of
these mutations in human and animal tissues (Wilson et al. 1999, 2000, 2001).  The
frequency of single base mutations in tissue samples can be determined over a range of
10-2 to 10-7 by adjusting either the amount of sample DNA analyzed by sampling a
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consecutively smaller number of genomes or reducing the number of PCR and RE cycles
in the selection process.
The approach to the Needle-in-a-haystack assay involved carefully selected nested
PCR primer pairs that were used to amplify specific regions of interest, specifically bases
1138 and 1620 (See Figure 4. for reference) of the FGFR-3 gene.  At least one primer set
overlapped the adjacent intron.  This is to ensure that DNA was being amplified from the
functional gene, not a pseudogene or RNA.  LCR primers were then designed for both
mutant and wild type sequences at each specific base site of interest.  The LCR primers
had discriminating bases at their 3’ ends.  These primers would only ‘match’ the template
DNA and ligate with the invariant primer if the correct base was in the coinciding spot on
the template DNA.  By changing the base at the 3’ end from C, A, G, or T, the base of the
template DNA at the coinciding location could be determined.  The Oligo 5.0 software
program was used to design primers with Tm values close to 65°C, which is also the
optimum temperature for thermostable ligase reactions (Taq ligase).  The variable
oligonucleotides were designed to have progressively longer 3’ poly-A tails, so that they
could be separated by size after the ligase reaction on sequencing gels.  The invariant
primers were labeled on their 5’ end with 32P so that they could be visualized on
radiographs.  Oligonucleotide mutant standards were used for assay verification and
validation.
7.1 APPROACH AT THE HYPOCHONDROPLASIA SITE
The assay for detecting the frequency of Hypochondroplasia causing mutations in the
FGFR-3 gene focused on the cytosine at base site 1620.  As mentioned previously, this
cytosine is substituted with either an adenosine or a guanine changing codon 540 from an
asparginine to a lysine (asn540lys or N540K).  This base site is located in exon 13 which is
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a 111 bp region in the proximal tyrosine kinase domain of the final protein receptor.
Primers were designed to flank this region and amplify the mutation with each additional
PCR amplification (Table 2.).  Table 3 gives the length in base pairs of the PCR products
of the various primer sets and the proper annealing temperatures used in the PCR reactions.
The restriction digestion with BspMI (5’-ACCTGC(N)4 -3’) was designed to digest the
wild type sequences and leave the mutated sequences (5’-ACATGC-3’ or 5’-ACGTGC-
3’).  LCR primers were then designed to detect and amplify the mutations at base number
1620 (Figure 5., Tables 4,5.).
Table 2.  Version 1 primer sequences and annealing temperatures for the PCR/RE selection
of the C1620A/G base change at codon 540 of the human FGFR3 gene.  The bold “T” in
the 6th position in primer T represents an incorporated base change designed to eliminate
an unwanted BspMI RE site.






Table 3.  Primer sets, annealing temperatures, and PCR product length of the Version 1
PCR protocol for the Hypochondroplasia site.




7.2 APPROACH AT THE ACHONDROPLASIA SITE
The assay for detecting the frequency of Achondroplasia causing mutations in the
FGFR-3 gene focused on the guanine at base site 1138.  As mentioned previously, this
guanine is substituted with either an adenosine or a cytosine.  This substitution changes
codon 380, which originally coded for the amino acid glycine, to an arginine residue
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Table 4.  LCR Version 1 primers and size in base pairs for the Hypochondroplasia site.
The bolded bases denote a designed base pair change.  The underscored bases in the
variant primers indicate the base which must be present at base pair 1620 for ligation to be
successful and yield product.















Table 5.  Sizes of LCR product, from both the sense and antisense strands, for the various
wild type (Wt) and mutant (Mt) primers for the Hypochondroplasia site.
DNA Strand Wt MtA MtG MtT
Sense 45 47 49 51
Antisense 48 50 52 54
(gly380arg or G380R).  Primers were designed to flank this region and amplify the
mutation with each additional PCR (Table 6.).  The primers were also designed to
incorporate a BsaJI restriction endonuclease site (5’-CCNNGG-3’) to allow for digestion
of wild type DNA because no restriction enzyme has been found to naturally cut at this
sequence.  These primers changed the original sequence from 5’-CTACGG-3’ to 5’-
CCACGG-3’ (site 1138 underscored).  With this new configuration, a mutation at site
1138 to an adenosine or a cytosine would not allow for digestion by BsaJI and only
original wild-type DNA would be cut.  Because of the requirement to incorporate a
restriction site, this protocol called for an initial PCR, followed by restriction endonuclease
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Figure 5.  LCR primer design for the detection of mutated sequences in the third base of
codon 540.  The invariant FGFR3c540s3LR and FGFR3c540s3L primers as well as the
discriminating WtFGFR3c540s3L and WtFGFR3c540sLR primers, are complementary to
the wild type sequence.  These primers will amplify the wild type product using the wild
type template in the LCR.  Primers Mts3GL and Mts3GLR, Mts3AL and Mts3ALR are
complimentary to the N540K mutation (AAC to AAG and AAC to AAA respectively).
Primers Mts3TL and Mts3TLR would amplify and ligate a thymine inserted at the third
spot, not a known mutation, but a primer to be used as a control.  These primers will ligate
to the invariant FGFR3c540s3L and FGFR3c540s3LR only in the presence of template
DNA containing the appropriate mutation.
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Table 6.  Version 1 primer sequences and annealing temperatures for the PCR/RE selection
of the G1138A/C base change of the human FGFR3 gene.  The bolded letters in the
primers represent incorporated base changes designed to incorporate a BsaJI restriction site
and to modify the sequence for controlled nested PCR procedures.









PR 5’-GCAGGCGGCAGAGCGTCA -3’ 75°C
YR2 5’-GTCACAGCCGCCACCACCAGGATGA -3’ 68°C
Table 7.  Primer sets, annealing temperatures, and PCR product length of the
achondroplasia site G1138A/C  protocol.




Table 8.  LCR assay for the achondroplasia site 1138 primers and size in base pairs.  The
bolded bases denotes a designed base pair change.  The underscored bases in the variant
primers indicate the base which must be present at base pair 1138 for ligation to be
successful and yield product.
















(RE) digestion.  LCR primers were then designed to detect and amplify the mutations at
base number 1138 (Tables 8, 9.).
Table 9.  Sizes of LCR product, from both the sense and antisense strands, for the various
wild type (Wt) and mutant (Mt) primers for the achondroplasia site 1138.
DNA Strand Wt MtA MtT MtC
Sense 44 41 45 47
Antisense 47 45 50 52
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CHAPTER 8.  MATERIALS AND METHODS
8.1 NEEDLE-IN-A-HAYSTACK ASSAY
• Enzymes
The Taq polymerases were purchased from Perkin-Elmer/Applied Biosystems
(Foster City, CA).  The LCR amplification enzyme was purchased from New England
Biolabs (Beverly, MA).  The restriction endonucleases BspMI, MspI, and BsaJI were also
purchased from New England Biolabs.  T4 polynucleotide kinase, for end-labeling, was
purchased from New England Biolabs.
• Oligonucleotides and radioactive isotopes
Oligonucletide PCR and LCR primers were custom synthesized by BioServe
Biotechnologies (Laurel, MD).  [ã-32P] ATP Redivue (>5000 Ci/mmol) was obtained from
Amersham (Arlington Heights, IL).
• Mutant and Genomic DNA
Human genomic DNA, at a concentration of 0.2 µg/µl, was purchased from
Boehringer Mannheim (Indianapolis, IN).  Mutant heterozygous DNA was obtained from
Dr. Gary Bellus (University of Colorado Health Sciences Center, Denver, CO).  Mutant
DNA came in concentrations of 200 and 25 ng/µl.  Samples of the G1138A and G1138C
achondroplasia mutations were provided.  Samples of the C1620A or C1620G
hypochondroplasia mutations were also provided.
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8.2 HYPOCHONDROPLASIA SITE
8.2.1 Mutant PCR and Restriction Endonuclease (PCR/RE) Selection of the
         Hypochondroplasia Site
Six µg of genomic DNA was combined with 6ng (10-3), 60 pg (10-5), or 6 pg (10-6)
of mutant DNA.  The combined DNA was then digested overnight with BspMI according
to manufacture’s recommendations in a minimum volume of 10 µl.
Proper amounts of commercial PCR buffer, MgCl, distilled water, nucleotides, and
PCR primer were then added to create a PCR readied solution with the total volume
brought to 50 µl.  The samples were then subjected to PCR amplification for 25 cycles
using the appropriate primers and annealing conditions (Primer set S-VR (521bp); 94°C
for 10 minutes to denature, 25 cycles of 1 minute 94°C denature, 1 minute 68°C annealing,
and 1 minute 72°C extension, and finished with 10 minutes at 72°C).  PCR amplification
was accomplished with the Perkin-Elmer 9700 instrument using 1U AmpliTaq Gold
(Perkin-Elmer) polymerase activity.  20 µl of the PCR reaction was then digested with
BspMI for up to 12 hours or overnight under the manufacturer’s specifications.
Two microliters of the restriction endonuclease digestion reaction was then
subjected to a second PCR amplification using nested primers and the appropriate
annealing conditions (Primer set T-WR (370bp); 94°C for 10 minutes to denature, 20
cycles of 1 minute 94°C denature, 1 minute 68°C annealing, and 1 minute 72°C extension,
and finished with 10 minutes at 72°C).  The same restriction digestion was performed on
20 µl of the second PCR solution as per manufacture’s recommendations.
Two microliters of the second digestion solution was then subjected to another
nested PCR (Primer set T-YR (249bp); 94°C for 10 minutes to denature, 20 cycles of 1
minute 94°C denature, 1 minute 68°C annealing, and 1 minute 72°C extension, and
finished with 10 minutes at 72°C).  A third and final digestion was performed on the
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samples.  A total of 3 restriction endonuclease digestions and three PCR amplifications for
a total of 65 cycles were performed on the samples prior to LCR analysis.
8.2.2 LCR and PAGE of the Hypochondroplasia Site
After the third and final restriction endonuclease digestion, 1 µl of the sample was
combined with 10-15 U Taq DNA ligase, 1 million cpm of 32P end-labeled invariant
primers, 1 µM of each wild type or each mutant discriminating primer (or a mixture of all
the discriminating primers, each at 1 µM concentration), 4 µg sheared salmon sperm, in
ligase buffer to a volume of 10 µl containing 20 mM Tris-HCl (pH 7.6), 100 mM KCl, 10
mM MgCl2, 1 mM EDTA, 10 mM dithiothreitol, 1 mM NAD
+, and 0.1% Tritron X-100.
Refer to Tables 4 and 5 for the sequences of the individual primers and LCR product size.
The LCR process was a two-temperature process using 94°C for denaturation and 65°C for
ligation.  The resulting ligation products were resolved on a 7 M urea, 10% acrylamide
sequencing gel.  The gel was then dried for approximately 40 minutes and exposed to x-ray
film for 15-60 minutes.
8.3 ACHONDROPLASIA SITE
8.3.1 Mutant PCR and Restriction Endonuclease (PCR/RE) Selection of the
         Achondroplasia Site
This protocol begins with a PCR amplification to incorporate the proper sequence
for the BsaJI restriction endonuclease.  Either 6 or 60 µg of genomic DNA was combined
with 6ng (10-3), 60 pg (10-5), or 6 pg (10-6) of mutant DNA.
Proper amounts of commercial PCR buffer, MgCl, distilled water, nucleotides, and
PCR primer were added to bring the total volume to 50 µl.  The samples were then
subjected to PCR amplification for 25 cycles using the appropriate primers and annealing
conditions (primer set A5-SR; 94°C for 10 minutes to denature, 25 cycles of 1 minute
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94°C denature, 1 minute 65°C annealing, and 1 minute 72°C extension, and finished with
10 minutes at 72°C).  PCR amplification was accomplished with the Perkin-Elmer 9700
instrument using 1U AmpliTaq Gold (Perkin-Elmer) polymerase activity.  20 µl of the
PCR reaction was then digested with BsaJI for up to 12 hours under the manufacturer’s
specifications.
Two microliters of the restriction endonuclease digestion reaction was then
subjected to a second PCR amplification using nested primers and the appropriate
annealing conditions (primer set N2-PR; 94°C for 10 minutes to denature, 20 cycles of 1
minute 94°C denature, 1 minute 65°C annealing, and 1 minute 72°C extension, and
finished with 10 minutes at 72°C).  The same restriction digestion was performed on 20 µl
of the second PCR solution as per manufacture’s recommendations.
Two microliters of the second digestion solution was then subjected to another
nested PCR (primer set N2-YR2; 94°C for 10 minutes to denature, 20 cycles of 1 minute
94°C denature, 1 minute 69°C annealing, and 1 minute 72°C extension, and finished with
10 minutes at 72°C).  A third and final digestion was performed on the samples.
A total of 3 restriction endonuclease digestions and three PCR amplifications for a
total of 65 cycles were performed on the samples prior to LCR analysis.
8.3.2 LCR and PAGE of the Achondroplasia Site
After the third and final restriction endonuclease digestion, 1 µl of the sample was
combined with 10-15 U Taq DNA ligase, 1 million cpm of 32P end-labeled invariant
primers, 1 µM of each wild type or each mutant discriminating primer (or a mixture of all
the discriminating primers, each at 1 µM concentration), 4 µg sheared salmon sperm, in
ligase buffer to a volume of 10 µl containing 20 mM Tris-HCl (pH 7.6), 100 mM KCl, 10
mM MgCl2, 1 mM EDTA, 10 mM dithiothreitol, 1 mM NAD
+, and 0.1% Tritron X-100.
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Refer to Tables 8 and 9 for the sequences of the individual primers and LCR product sizes.
The LCR process was a two-temperature process using 94°C for denaturation and 65°C for
ligation.  The resulting ligation products were resolved on a 7 M urea, 10% acrylamide
sequencing gel.  The gel was then dried for approximately 40 minutes and exposed to x-ray
film for 15-60 minutes.
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CHAPTER 9.  RESULTS
9.1 Results of the PCR/RE/LCR of the Hypochondroplasia Site
During the preliminary primer check for PCR and restriction endonuclease
reliability of this assay, it was discovered that in addition to the BspMI restriction site at
codon 540, there were three other restriction sites within the amplified region of the DNA.
Since these restriction sites yielded fragmented DNA after the digestions that could not be
amplified in the ligase chain reaction, new primer sequences were designed.  These second
version primers were then used in the same manner as previously described for the first
version (First PCR set, S-ZR; Second PCR set, T-ZR; Third PCR set, U-YR)  (Table10.).
Table 10.  Version 2 primer sequences and annealing temperatures for the PCR/RE
selection of the C1620A/G base change at codon 540 of the human FGFR3 gene.  The
bolded “A” in primer ZR and the bolded “T” in primer T represent an incorporated base
change designed to eliminate any unwanted primer/dimer formations.






Another problem was then encountered with the second version primer set.
Digestion of the PCR product was highly inefficient with BspMI (Figure 6.).  It was
estimated that restriction only reached approximately 25%.  This inefficiency in digestion
was unacceptable if maximum sensitivity of the needle-in-a-haystack protocol was to be
attained.
It has been noted that the BspMI restriction enzyme can produce inefficient
digestion at resistant DNA sequences (Oller et al. 1991).  The use of additional cleavable
DNA or spermidine has been shown to be able to boost efficiency to acceptable levels.  For
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this assay, spermidine and φX174 DNA were added separately and together to the PCR
mixtures before restriction endonuclease digestion.  Spermidine was added at
concentrations between 0.5 and 3.0 mM to the digestion reactions.  φX174 DNA was
added at a concentration between 0.14 and 1.4 nM.  Neither of these techniques helped to
increase the efficiency of the digestion reaction (Figures 7, 8.).
Since LCR depends on a successful selection process, multiple attempts were made
to refine the second version digestion protocol.  Multiple combinations of spermidine and
φX174 DNA concentrations were added to the reaction mixtures to try and increase
digestion product.  Increased concentrations of enzyme as well as increased lengths of time
were also used to try and increase efficiency.  Neither technique was able to increase the
efficiency of restriction with BspMI (Figure 8.).
In conjunction with the PCR and RE trials, initial steps were taken to refine the
LCR technique for site 1620.  Figure 9 shows the successful LCR product formation with
wild-type DNA and standard mutant DNA templates.  The wild-type DNA was PCR
product from primer set U-YR.  The bands on the PAGE gel only represent the sense
strands but further adjustments would have produced both sense and antisense bands (See
Table 5 for appropriate sizes of LCR product).
9.2  Incorporation of a MspI Restriction Site
It was finally determined that the BspMI would fail to ever give the desired
digestion efficiency.  A new set of primers were then developed to incorporate a MspI
restriction endonuclease site at codon 540 (Table 11.).  In order to accomplish this, the
downstream primer of the first set was designed to alter the sequence at codon 541 from
5’-CTG-3’ to 5’-CGG-3’.  This would give a new sequence of 5’-AACCGG-3’ at codons
47
Figure 6.  Agarose gel of the PCR products and restriction products of the three PCR
primer sets comparing the efficiency of restriction of BspMI based on time.  Lane 1 – S-ZR
at 1 hour.  Lane 2 – S-ZR at 24 hours.  Lane 3 – T-YR at 1 hour.  Lane 4 – DNA Ladder.
Lane 5 – T-YR at 24 hours.  Lane 6 – U-YR at 1 hour.  Lane 7 – U-YR at 24 hours.
Results show a moderate increase in efficiency with a longer time for restriction.
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Figure 7.  Agarose gel of the PCR products of primer set S-ZR with restriction with BspMI
and the addition of φX174 DNA to increase efficiency.  Lane 1 – 1.4 nM φX174 DNA.
Lane 2 – HiLo Ladder.  Lane 3 – 1.0 nM φX174 DNA.  Lane 4 – HiLo Ladder.  Lane 5 -
0.14 nM φX174 DNA.  Results showed no increase in efficiency with the addition of
φX174 DNA.  (The bands in the top of the PCR product lanes are restriction remnants of
φX174 DNA).
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Figure 8.  Agarose gel of the PCR products of primer set T-YR with restriction with BspMI
and the addition of spermidine to increase efficiency.  Lane 1 – 0.5 mM spermidine.  Lane
2 – 1.0 mM spermidine.  Lane 3 – 1.5 mM spermidine.  Lane 4 – DNA Ladder.  Lane 5 –
2.0 mM spermidine.  Lane 6 – 2.5 mM spermidine.  Lane 7 – 3.0 mM spermidine.  Results
showed no increase in efficiency with the addition of spermidine.
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Figure 9.  Autoradiograph of a first version LCR testing the Wt and Mt primers and
oligonucleotide standards.  Primers used are listed at the top of each lane.  The template
used in each lane is as follows:  Lane 1 – Human genome DNA (HG).  Lane 2 – HG.  Lane
3 – HG.  Lane 4 – Oligonucleotide T mutation standard (TLstd) (1pm).  Lane 5 – TLstd
(0.025pm).  Lane 6 – Oligonucleotide A mutation standard (ALstd) (1pm).  Lane 7 –
ALstd (0.025pm) .  Lane 8 – Oligonucleotide G mutation standard (GLstd) (1pm).  Lane 9
– GLstd (0.025pm).  Lane 10 – Blank.  Lane 11 – Blank.  Lane 12 – Standard mix (1pm).
Lane 13 – Standard Mix (0.025pm).
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540 and 541 (codon 540 underlined) at which MspI would then digest the wild-type
sequences.
It should also be noted that several mismatches were incorporated into primers
MspIR and ZR2.  If successful incorporation of an MspI restriction site occurred with
primers MspIR and S, then these mismatched bases would also be incorporated into the
PCR product.  The same sequence of incorporated base pairs was created in primer ZR2,
the downstream primer of the second PCR.  Thus, only DNA with the proper MspI
restriction site would serve as template for the second PCR.  Figure 10 shows a schematic
of the PCR and restriction endonuclease selection process for site 1620.
Table 11.  Version 3 primer sequences and annealing temperatures for the PCR/RE
selection of the C1620A/G base change at codon 540 of the human FGFR3 gene.  The
bolded bases in primer MspIR and in ZR2 represent mismatch pairs with the wild type
DNA incorporated in order to restrict the template for the second PCR to be limited to first
PCR product that had inserted the correct MspI sequence.







ZR2 5’- GTAGTCGGGTTAA TGGATGTAGTGC-3’ 64°C
Figure 11 shows the agarose gel of successful sequential PCR selection processes.
Primer pairs S-MspIR gave a 239 base pair product, primer pairs T-ZR2 gave a 206 base
pair product, and primer pair U-ZR2 gave a 141 base pair product.  MspI was also able to
give efficient restriction at the incorporated site.
The PCR primers were then tested on human mutant C1620G and C1620A DNA.
Figure12 gives the Agarose gel of successful PCR (primer set S-MspIR) and restriction
with MspI.  The restriction of the mutant PCR product shows only about 50% efficiency.
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Figure 10.  Schematic representation of the incorporation of the restriction endonuclease
recognition sequence 5’-CCGG-3’ for MspI.  The first PCR uses primer set S-MspIR to
incorporate the MspI recognition sequence and produce a 239bp product.  The second
nested PCR uses primer set T-ZR2 to produce a 206bp product.  Primer ZR2 is specific for
DNA template which has incorporated the MspI recognition sequence.  The third nested
PCR uses primer set U-ZR2 to produce a 141bp product.  The box represents the DNA
sequence that was altered to incorporate the recognition sequence for MspI.
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This is a good result because of the nature of the hypochondroplasia mutation.  Since
hypochondroplasia is a heterozygous dominant mutation (paternal allele), half of the PCR
product representing the paternal allele would be mutated and resist restriction and half of
the product representing the maternal allele would be wild-type and succumb to restriction.
Since all of the PCR primers were showing proper function, and the MspI
restriction enzyme was giving efficient restriction, the LCR assay was then designed to
accompany this new set of PCR primers.
9.3 Design of the Second Version of the LCR Assay at Site 1620
Because new sequences were incorporated into what would be the template for the
LCR procedure, new LCR primers were designed to comply with these changes.  Table 12
gives the new discriminating sense and antisense primers as well as the invariant primers.
It should be noted that the discriminating sense strand primers did not change with the new
set.  Figure 13 gives a schematic of the new LCR procedure.  The oligonucleotide
standards were not changed to carry the ‘G’ and ‘T’ changes that were incorporated into
the product DNA during the PCR amplification with the MspIR primer.
9.4 LCR Results for Site 1620
Figure 14 gives the results of the first attempt to determine the compatibility of the
LCR primers with various PCR products.  The results showed that the wild-type LCR
primers will produce both sense and antisense products with wild-type DNA as the
template.  There was, however, some contamination with extra bands between the sense
and antisense strands.  This is not unusual with the amount of PCR/RE primers, enzymes,
and reagents that have accumulated during the first steps.  It was also determined that the
mutant LCR primers both by themselves and in a mix would not form product with wild-
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Figure 11.  Agarose gel of successful nested PCR/RE sequences.  Lane 1- HiLo Ladder.
Lane 2 – PCR product with S-MspIR of human genomic DNA.  Lane 3 – Restriction of
product from Lane 1 with MspI.  Lane 4 – PCR of product from Lane 3 with primer set T-
ZR2.  Lane 5 - Restriction of product from Lane 4 with MspI.  Lane 6 - PCR of product
from Lane 5 with primer set U-ZR2.  Lane 7 – Restriction of product from Lane 6 with
MspI.  Lane 8 – HiLo Ladder.  The 239bp PCR product in Lane 4 can be attributed to left
over primers in subsequent reactions.  It should also be noted that the increasing intensity
around the 50bp size range in Lane 4 and on can be attributed to the build up of the MspIR
primer (49mer) and small fragment digestion product of T-ZR2 (48bp) and U-ZR2 (48bp).
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Figure 12.  Agarose gel of successful PCR with primer set S-MspIR on wild-type human
genomic DNA and human mutant C1620G and C1620A with subsequent restriction with
MspI.  Lane 1- HiLo Ladder.  Lane 2 – Human genomic DNA.  Lane 3 – restriction of
Lane 2 product.  Lane 4 – Human genomic DNA.  Lane 5 – restriction of Lane 4 product.
Lane 6 – Mutant C1620G DNA.  Lane 7 – restriction of Lane 6 product.  Lane 8 – Mutant
C1620G DNA.  Lane 9 – restriction of Lane 8 product.  Lane 10 – Mutant C1620A DNA.
Lane 11 – restriction of Lane 10 product.  Lane 12 – Mutant C1620A DNA.  Lane 13 –
restriction of Lane 6 product.  Lane 14 – Blank DNA.  Lane 15 – restriction of Lane 14
product.  Lane 16 – HiLo Ladder.
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Table 12.  LCR Version 2 primers and size in base pairs.  The bolded bases denote a
designed base pair change to coincide with the incorporated base pair changes from the
PCR/RE series.  The underscored bases in the variant primers indicate the base which must
be present at base pair 1620 for ligation to be successful and yield product.















Table 13.  Sizes of LCR product, from both the sense and antisense strands, for the various
wild type (Wt) and mutant (Mt) primers for the second LCR design.
DNA Strand Wt MtA MtG MtT
Sense 45 47 49 51
Antisense 51 53 55 57
type DNA as the template.  Both of these results were good in that the assay would
probably not produce false positives in the presence of wild-type DNA.
However, this attempt at forming product with mutant primers using mutant
oligonucleotide standards (at 1 picomole per reaction) as LCR templates proved
unsuccessful.  It should also be noted that the mutant oligonucleotide standards did not
carry the ‘G’ and ‘T’ changes that were incorporated into the LCR mutant primers to
coincide with the base changes produced in the template DNA during the PCR process.
The DNA used here for template (except for the standard oligonucleotides) was produced
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Figure 13.  LCR primer design for the detection of mutated sequences in the third base of
codon 540.  The invariant FGFR3c540s3LR2 and FGFR3c540s3L2 primers as well as the
discriminating WtFGFR3c540s3L and WtFGFR3c540sLR2 primers, are complementary to
the wild type sequence.  These primers will amplify the wild type product using the wild
type template in the LCR.  Primers Mts3GL and Mts3GLR2, Mts3AL and Mts3ALR2 are
complimentary to the N540K mutation (AAC to AAG and AAC to AAA respectively).
Primers Mts3TL and Mts3TLR2 would amplify and ligate a thymine inserted at the third
spot, not a known mutation, but a primer to be used as a control.  These primers will ligate
to the invariant FGFR3c540s3L2 and FGFR3c540s3LR2 only in the presence of template
DNA containing the appropriate mutation.  LCR product fragment sizes are listed in Table
13.
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 from human genomic DNA with the second nested PCR (primers T-ZR2), after restriction
following the first PCR.  The first PCR (primer set S-MspIR) used 200ng of wild-type
human genomic DNA.
Because the mutant standard oligonucleotide did not ligate successfully, the focus
was turned to refining the efficiency of mutant primers ligating with oligonucleotide
standards as the template.  The concentration of the standard was decreased from 1
picomole to 0.025 picomoles per reaction.  This again, however, was not successful in
producing ligation.   Figure 15 gives these results.  Figure 15 also shows the first attempt to
form LCR product using human mutant DNA (both the C1620G and C1620A mutations
after the second nested PCR (T-ZR2) without restriction) as template with mutant primers.
The first PCR (primer set S-MspIR) used 200ng of mutant human genomic DNA for both
the C1620G and the C1620A mutations.  The mutant primers were unsuccessful in forming
product with the mutant DNA.  The LCR reaction itself was not the problem in this run
because of the positive results with wild-type DNA and wild-type primers and the negative
result with mutant and wild-type primers without DNA.
 Figure 16 gives the results of an attempt to refine the actual LCR reaction.  The ligation
reaction was run at a temperature of 64°C instead of the standard 65°C.  Lowering the
reaction temperature, while increasing the potential for increased ligation, has the tendency
to create increased false positives.  The DNA used to test the wild-type primers was PCR
product made with the third set of primers U-ZR2 on human genome DNA (PCR product
was not restricted between PCR sets; they were only sequential nested PCRs).  The first
PCR (primer set S-MspIR) used 200ng of wild-type human genomic DNA.  Wild-type
primers were successful in giving sense product (45bp) and antisense product (51bp)
showing that the reaction could work with these primers at 64°C.
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       Figure 14. Autoradiograph of a second version LCR testing the Wt and Mt primers 
and oligonucleotide standards.  Primers used are listed at the top of each lane.  The 
template used in each lane is as follows:  Lane 1 – HG.  Lane 2 – HG.  Lane 3 –  
HG.  Lane 4 – HG.  Lane 5 – HG.  Lane 6 – ALstd (1pm).  Lane 7 – GLstd (1pm).
Lane 8 – TLstd (1pm).  Lane 9 – Standard Mix (1pm).  Lane 10 – HG.  Lane 11 – 
Blank.  Lane 12 – Blank.
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 The mutant primers were also tested for their ability in this LCR at 64°C.  Mutant
standards for the C1620A (MtA) mutation and the C1620G (MtG) mutation and the
C1620T (MtT) mutation were tested separately and together as a mix along with the
mutant primers for each of the mutation types (MtA, MtG, and MtT each separately with
their corresponding mutations and as a mix).  The only standard and mutant primer pair to
ligate successfully at this temperature was the mutant T antisense primer with the mutant T
standards (57bp).  The MtT oligonucleotide standard was able to serve as template both by
itself and in the mix.
The LCR mutant primers’ ability to ligate with human mutant DNA was also tested
in this LCR run.  The MtG primer, both by itself and in a mutant primer mix was able to
ligate human mutant C1620G DNA to give both sense (49bp) and antisense (55bp)
products.  The MtA primer, both by itself and in a mutant primer mix was also able to
ligate human mutant C1620A DNA to give both sense (47bp) and antisense (53bp)
products.  The mutant DNA used in this run was human mutant DNA that was subjected to
the first round of PCR with primer set S-MspIR then digested with MspI.  The first PCR
(primer set S-MspIR) used 200ng of wild-type human genomic DNA.  The DNA was then
subjected to a nested second round of PCR with primer set T-ZR2 and again digested with
MspI.  The mutant mix primers also showed some ability to ligate wild-type DNA.  The
wild-type and mutant primers did not form any product when run without any DNA in the
reaction, evidence that the primers themselves can not form spontaneous products at this
temperature.
 Figure 17 was an attempt to refine the mutant standard for the C1620T mutation at
64°C.  This mutation does not occur naturally, however, because it showed promise of
being a good standard, the technique was altered in order to get both sense and antisense
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Figure 15.  Autoradiograph of an LCR test with decreased concentration of oligonucleotide
standards and mutant DNA with the Mt primers.  Primers used are listed at the top of each
lane.  The template used in each lane is as follows:  Lane 1 – HG.  Lane 2 – ALstd
(0.25pm).  Lane 3 – GLstd (0.25pm).  Lane 4 – TLstd (0.25pm).  Lane 5 – Std Mix
(0.25pm).  Lane 6 – Mutant C1620G.  Lane 7 – Mutant C1620G.  Lane 8 – Mutant
C1620A.  Lane 9 – Mutant C1620A.  Lane 10 – HG.  Lane 11 – Blank.  Lane 12 – Blank.
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Figure 16.  Autoradiograph of an LCR run at 64°C using HG DNA and mutant DNA with
the wild-type and mutant primer sets.  Primers used are listed at the top of each lane.  The
template used in each lane is as follows:  Lane 1 – HG.  Lane 2 – ALstd (1pm).  Lane 3 –
GLstd (1pm).  Lane 4 – TLstd (1pm).  Lane 5 – HG.  Lane 6 – C1620G.  Lane 7 –
C1620G.  Lane 8 – C1620A.  Lane 9 – C1620A.  Lane 10 – HG.  Lane 11 – Blank.  Lane
12 – Blank.
63
product formed.  The human wild-type and mutant (C1620A) DNA was also cleaned with
the Qiagen PCR clean-up kit in order to clean the extra bands seen between the wild-type
sense and antisense bands.  These results show that cleaning the PCR/RE product before
running the LCR reaction did in fact remove the extra bands.  The mutant C1620A LCR
product did not show any difference between ‘clean’ and ‘dirty’ PCR/RE product.
The MtT oligonucleotide standards in this run were also diluted from 1 picomole
per reaction down to 0.008 picomoles per reaction.  It was believed that the large
concentration of oligonucleotide standards compared to primers was interfering in the LCR
reactions ability to form the sense strand product.  Results showed that no amount of
dilution could aid in producing the sense strand.  If the other mutant primers behaved this
way it would be very detrimental because it is the sense product of the LCR reaction that
gives the actual base change that leads to hypochondroplasia.  Having only the antisense
product is adequate for evidence of mutation, however, in order to declare mutation with
absolute certainty, both the sense and antisense bands must be present.
 In order to increase the efficiency of the LCR reaction, the temperature was again
lowered to 62°C.  The MtT standard was also diluted from 0.016 picomoles down to
0.0001 picomoles per reaction.  The ‘cleaned’ PCR product was used for wild-type and
mutant C1620A template.  The human mutant C1620G DNA was also tested at this new
temperature.  The DNA templates were products from the second digestion reaction after
the second PCR (T-ZR2).  200ng of both wild-type human genomic and human mutant
DNA were used in the first PCR.
 The results of this new technique are shown in Figure 18.  At the new temperature
the ‘clean’ wild-type PCR product produced extra bands between the sense and antisense
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Figure 17.  Autoradiograph of an LCR testing progressively decreasing concentrations of
oligonucleotide standard T with the MtT primer.  ‘Clean’ DNA was also tested in this run
to compare the product bands with ‘dirty’ DNA.  Primers used are listed at the top of each
lane.  The template used in each lane is as follows:  Lane 1 – ‘Dirty’ HG.  Lane 2 – ‘Clean’
HG.  Lane 3 – ‘Dirty’ C1620A.  Lane 4 – ‘Clean’ C1620A.  Lane 5 – HG.  Lane 6 – TLstd
(1pm).  Lane 7 – TLstd (0.5pm).  Lane 8 – TLstd (0.25pm).  Lane 9 – TLstd (0.125pm).
Lane 10 – TLstd (0.0625pm).  Lane 11 – TLstd (0.032pm).  Lane 12 – Blank.  Lane 13 –
Blank.
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bands.  The MtT standards began to produce both sense and antisense bands with the
oligonucleotide mutant standard at 0.016 picomoles in the reaction at this temperature.
With the LCR reaction at 62°C, many components of the assay were working with
some degree of success.  The human wild-type DNA was working as a template for the
wild-type primers and the human wild-type DNA was not serving as template for any of
the mutant primers.  The wild-type and mutant primers were also not spontaneously
forming LCR product in the absence of DNA.  In addition, the mutant primers were
forming both sense and antisense bands with the mutant primers at 62°C. The MtT
standard was also serving as template for the MtT primers to form both sense and antisense
bands at a concentration of 0.016 picomoles per reaction.  Because all of these components
were working with some degree of accuracy, a full selection process was attempted to
achieve a 1-in-a-million detection sensitivity.
The results of the PCR/RE/LCR selection process are shown in Figure 19.  The
positive result with wild-type primers and wild-type DNA template ensured the LCR
reaction was working successfully.  The MtT oligonucleotide standard at a concentration
of 0.002 picomoles also produced sense and antisense bands.  The human mutant DNA
was combined with human wild-type DNA at various concentrations to get varying
degrees of sensitivity.  The sensitivity of detection corresponds to the number of mutant
genomes detected in the presence of 2x106 wild-type genomes (106 cells).  For instance, 1
in 100 would correspond to 1 mutant genome in 100 wild-type cells.  Table 14 gives the
amounts of DNA used and the resulting sensitivities.
The LCR assay in Figure 19 showed bands produced with 6 µg of wild-type DNA
with a mutant primer mix.  The bands corresponded with the sense and antisense strands of
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Figure 18.  Autoradiograph of an LCR run at 62°C.  This run was used to test 
progressive dilutions of the oligonucleotide mutant T standard.  Note that the 
PAGE ran skewed and the size of the bands do not line up precisely from left to 
right.  The scale on the left should be used for Lanes 1-8 and the scale on the right 
should be used for Lanes 9-13.  Primers used are listed at the top of each lane.  The 
template used in each lane is as follows:  Lane 1 – ‘Clean’ HG.  Lane 2 – ‘Clean’ 
C1620A.  Lane 3 – ‘Clean’ C1620A.  Lane 4 – TLstd (0.016pm).  Lane 5 – TLstd 
(0.008pm). Lane 6 – TLstd (0.004pm).  Lane 7 – TLstd (0.002pm).  Lane 8 – TLstd
(0.001pm).  Lane 9 – C1620G.  Lane 10 – C1620G.  Lane 11 – C1620G.  Lane 12 
– Blank.  Lane 13 – Blank.
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the MtT primer set.  This set had previously not appeared with other LCR runs.  However,
this was the first run using such a large amount of DNA, 6 µg compared with 200 ng.  This
run did show successful ligation of both sense and antisense wild-type primers with 6 µg of
human wild-type DNA.
Table 14.  Amount of mutant DNA combined with 6 µg of wild-type DNA to reach
the desired sensitivities.
Wild-type DNA Mutant DNA Sensitivity
6 µg 600 ng 1 in 100
6 µg 0.6 ng 1 in 10,000
6 µg 0.06 ng 1 in 100,000
6 µg 0.006 ng 1 in 1,000,000
This assay was able to obtain sensitivity (ligation of both sense and antisense
primers) of 1 in a 100 with the C1620G mutation.  However, there was ligation of the MtT
primers at each of the sensitivities.  It is uncertain if these false positives came from
spontaneous ligation, ligation from wild-type template, or ligation from mutant template.
This assay was also able to obtain sensitivities of 1 in 100 (sense and antisense
band), 1 in 10,000 (antisense band), 1 in 100,000 (antisense band), and possibly 1 in
1,000,000 (very faint antisense band) with the C1620A mutation.  However, there was also
ligation of the MtT primers at each of the sensitivities as well.
9.5 Design of the Third Version of the LCR Assay at Site 1620
Because the second version of the LCR assay at site 1620 was not successful, a
third version was designed.  The principle behind changing the design was to try and
decrease the number of false positives created with the MtT primers and do adapt the LCR
primers for efficient ligation at 65°C rather than 62°C.  This was attempted by shortening
the L invariant primer and incorporating base changes in the MtT and MtA sense strand
primers.
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Figure 19.  Autoradiograph of the 2nd version LCR with the selection process.  Primers
used are listed at the top of each lane.  The template used in each lane is as follows:  Lane
1 – HG.  Lane 2 – TLstd (0.002pm).  Lane 3 – 6 ìg Wt (with selection).  Lane 4 – 6ìg Wt
(with selection).  Lane 5 – C1620G (10-2).  Lane 6 – C1620G (10-4).  Lane 7 – C1620G
(10-6).  Lane 8 – C1620G (10-6).  Lane 9 – 6 ìg Wt (with selection).  Lane 10 – 6ìg Wt
(with selection).  Lane 11 – C1620A (10-2).  Lane 12 – C1620A (10-4).  Lane 13 – C1620A
(10-6).  Lane 14 – C1620A (10-6).  Lane 15 – Blank.  Lane 16 – Blank.  Lane 17 – Blank.
Lane 18 – Blank.
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Table 15 gives the new primers for the third version of the LCR assay.  It should be
noted that the Mts3GL and WtFGFR3c540s3L were not changed.  The antisense
discriminating primers were not altered either.
Table 15.  LCR Version 3 primers and size in base pairs.  The bolded bases denote a
designed base pair change to coincide with the incorporated base pair changes from the
PCR/RE series.  The underscored bases in the variant primers indicate the base which must
be present at base pair 1620 for ligation to be successful and yield product.  The lower case
bases are the base changes specific for the version 3 LCR.















Table 16.  Sizes of LCR product, from both the sense and antisense strands, for the various
wild type (Wt) and mutant (Mt) primers for the third LCR design.
DNA Strand Wt MtA MtG MtT
Sense 42 44 46 48
Antisense 51 53 55 57
Figure 20 gives the results of an LCR performed with a mixture of components
from the second and third version of the LCR techniques.  The purpose of this run was to
determine which groups of invariant and discriminating primers worked the most
efficiently together.  Both L2 and L3 worked with LR3 to produce both sense and
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Figure 20.  Autoradiograph of an LCR run at 65°C testing the compatibility of the 3rd
version mutant primers with the 2nd and 3rd version invariant primers.  Primers used are
listed at the top of each lane.  A ‘*’ denotes version 2 invariant primers, a ‘’ denotes
version 3 invariant primers.  The template used in each lane is as follows:  Lanes 1-10 –
HG.  Lanes 11-13 – C1620A.  Lanes 14-16 – C1620G.  Lanes 17-19 – Blank.
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antisense bands (L2 and LR3: 51bp and 45bp; L3 and LR3: 51bp and 45bp).  The invariant
primer combinations L2/LR3 and L3/LR3 both failed to ligate with both versions 2 and
version 3 mutant primer mixes using wild-type DNA as the template, indicating that
neither combination should give a mutant false positive with wild-type DNA.  However,
both showed faint bands corresponding to ligation of the MtT primers.
The version 3 mutant primers for the ‘T’ mutation did, however, ligate to produce
intense bands with wild-type template when the MtT primers were used alone with the
L2/LR3 combination of invariant primers and the L3/LR3 combination.  The version 2
MtT primer by itself did not produce bands at all when it was used with the L2/LR3
combination of invariant primers and the L3/LR3 combination, though.
The ability of the version 3 mutant primers and invariant primer combinations to
ligate using human mutant C1620A and C1620G DNA as template was also tested in this
run.  The version 3 primers were able to form product with both C1620A and C1620G
templates using both the L2/LR3 and L3/LR3 combinations.  The version 2 primers also
showed the ability to form product with both C1620A and C1620G templates using both
the L2/LR3 and L3/LR3 combinations.  These results also showed that the version 3
mutant primers would not spontaneously form ligation product with either the L2/LR3 or
L3/LR3 invariant primers without the presence of DNA.
The results of the previous LCR run gave very mixed results, but it was determined
that the third version LCR mutant primers and the L3/LR3 invariant primers would
potentially give the best results.  Figure 21 gives the results of the selection procedure with
these new components.  The LCR reaction was run at 62°C.
This run showed basically the same problems as the last run of the version 2 LCR
reaction (Figure 19).  While selection was reached at a sensitivity of 1 in 100 for the
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C1620G mutation the C1620A sensitivity only reach 1 in 100, where previously it had
possibly reached a little higher sensitivity.  There was also a great deal of false positives
with the formation of MtT LCR product whenever the MtT primers were present.
It was believed that the possible reason for low efficiency at lower sensitivities was
that the MtT primers were interfering with the reaction.  The LCR of the selection was then
run without the presence of the MtT primers in the hope that a greater sensitivity could be
obtained.  Figure 22 gives the results from this run.  Neither the C1620G nor the C1620A
mutation reached a greater sensitivity than 1 in 100.
Because of the lack of progress at site 1620 for the hypochondroplasia mutation to
this point, it was determined that the PCR/RE/LCR assay would not work.  The results
given here represent the most significant changes in the techniques of the assay.  Many
other variables were attempted to be altered, i.e. changing buffer pHs and concentrations,
changing concentrations of various enzymes, changing lengths of restrictions, etc.
However, no significant results were obtained by these attempts.  Therefore, the attempt to
develop an assay to determine the frequency of the C1620G/A hypochondroplasia causing
mutation was terminated.
9.6 Allele Specific PCR Results for Site 1138
Many attempts were made previously in this lab to refine the PCR/RE/LCR
technique for the G1138A/C achondroplasia mutation (personal communication, V.L.
Wilson).  As with the hypochondroplasia site, 1 in 1,000,000 sensitivity was never
obtained.  The PCR/RE/LCR technique discussed in Chapter 8 was the last version used by
the lab and this technique was the basis for the next attempt to achieve sensitivity at site
1138.
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Because the Needle-in-a-Haystack technique for determining frequency of mutation
in a population of cells would not work, another approach was implemented.  Since
achondroplasia is more prevalent than hypochondroplasia in the population it was
determined that an allele-specific PCR technique in conjunction with the selection process
would be designed for the G1138A/C achondroplasia causing mutation.
This technique would use the same selection process as mentioned before in
Chapter 8 to amplify progressively smaller amounts of the G1138A/C mutation in a large
amount of wild-type DNA.  At the point where the LCR was to determine the sensitivity,
allele specific PCR was substituted.
The approach for the allele specific PCR was quite simple.  The 3’ end of three
different oligonucleotide primers were designed to match with whatever base was present
at site 1138.  Table 17 gives the allele specific primers used in this technique.  Figure 23
gives a schematic behind the design of the allele specific primers.  The upstream primer in
this technique was the allele specific primers while the downstream primer was primer
YR2 (see table 6 for sequence).
Table 17.  Primer sequences and sizes for the allele specific PCR technique at site 1138.
The underscored bases correspond to site 1138.




Figure 24 gives the initial trial run of the allele specific primers.  This PCR was run
at a temperature of 60°C.  The asWt (allele specific wild-type) primer successfully primed
and formed the correct 58bp product.  However, both of the mutant primers also primed
the wild-type DNA to form false positives.  All of the allele specific primers failed to form
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Figure 21.  Autoradiograph of an LCR of the selection process to test acquired sensitivity.
Primers used are listed at the top of each lane.  The template used in each lane is as
follows:  Lane 1 – HG.  Lane 2 – HG.  Lane 3 – 6 ìg Wt (with selection).  Lane 4 – 6ìg Wt
(with selection).  Lane 5 – HG.  Lane 6 –  6 ìg Wt (with selection).  Lane 7 – C1620A.
Lane 8 – C1620A (10-2).  Lane 9 – C1620A (10-4).  Lane 10 – C1620A (10-6).  Lane 11 –
C1620G.  Lane 12 – C1620G (10-2).  Lane 13 – C1620G (10-4).  Lane 14 – C1620G (10-6).
Lane 15 – Blank.  Lane 16 – Blank.  Lane 17 – Blank.  Lane 18 – Blank.
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Figure 22.  Autoradiograph of LCR selection process using a mutant primer mix that does
not contain the MtT primers.  Primers used are listed at the top of each lane.  The template
used in each lane is as follows:  Lane 1 – HG.  Lane 2 – HG.  Lane 3 – 6 ìg Wt (with
selection).  Lane 4 – 6 ìg Wt (with selection).  Lane 5 – C1620A.  Lane 6 – C1620A (10-2).
Lane 7 – C1620A (10-4).  Lane 8 – C1620A (10-6).  Lane 9 – C1620G.  Lane 10 – C1620G
(10-2).  Lane 11 – C1620G (10-4).  Lane 12 – C1620G (10-6).  Lane 13 – Blank.  Lane 14 –
Blank.  Lane 15 – Blank.  Lane 16 – Blank.
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Figure 23.  Schematic representation of the allele specific PCR at site 1138.   The
underscored ‘G’ represents site 1138.  The asMtA primer will only prime if a ‘A’ is located
at site 1138.  The asMtC will only prime if there is a C at site 1138.
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false positives in the reaction without DNA.  The asMtA (allele specific mutant A) primer
was also able to prime mutant G1138A template to form product, however, the asWt
primer also primed to form product.  The formation of product with asWt primers and
G1138A mutant DNA template was an acceptable result because the achondroplasia
mutation is heterozygous, therefore half of its genome is wild-type.  However, the asMtC
(allele specific mutant C) also formed product with the mutant G1138A template,
suggesting that at 60°C there is not enough discrimination among the primers to prevent
false positives.
The temperature of the PCR was then adjusted in order to refine the procedure and
eliminate the false positives.  The same assay was then run at 65°C, 58°C, and 59°C.  The
results at each of these temperatures are given in Figures 25-27.  The new temperatures all
gave the same false positives.  The amount of template DNA was also cut in half in order
to increase efficiency and decrease the template for possible false positives.  Figure 28
gives these results which was the same a previous runs with the same amount of DNA.
It was determined that the allele specific primers did not have the ability to
discriminate sufficiently at site 1138.  The allele specific primers for both the wild type
and the mutant G1138A mutation were then both redesigned.  The base immediately
upstream of the base corresponding to site 1138 was mismatched in order to help with
the accuracy of the primers hydrogen bonding at site 1138.  It was believed that with this
mismatch, the base at site 1138 of the primer must match exactly with the base at site 1138
of the template in order to prime.
Figure 29 gives the results of the new primers at 65°C.  The asWt primer produced
product with wild-type DNA, however the asMtA2 primer also formed product with wild-
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Figure 24.  Agarose gel of the test run with the allele specific wild-type and mutant primers
at 60°C.  Lane 1 – HiLo Ladder.  Lanes 2-4 – Wild-type DNA.  Lanes 5-7 – Blank DNA.
Lanes 8-10 – G1138A Mutant DNA.  Lane 11 – HiLo Ladder.
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Figure 25.  Agarose gel of the test run with the allele specific wild-type and mutant primers
at 65°C.  Lane 1 – HiLo Ladder.  Lanes 2-4 – Wild-type DNA.  Lanes 5-7 – Blank DNA.
Lanes 8-10 – G1138A Mutant DNA.  Lane 11 – Primer N2 used to test the PCR reaction
mix, however, 65°C is not the optimal Tm.  Lane 12 – HiLo Ladder.
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Figure 26.  Agarose gel of the test run with the allele specific wild-type and mutant primers
at 58°C.  Lane 1 – HiLo Ladder.  Lanes 2-4 – Wild-type DNA.  Lanes 5-7 – Blank DNA.
Lanes 8-10 – G1138A Mutant DNA.  Lane 11 – Primer N2 used to test the PCR reaction
mix.  Lane 12 – HiLo Ladder.
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Figure 27.  Agarose gel of the test run with the allele specific wild-type and mutant primers
at 59°C.  Lane 1 – HiLo Ladder.  Lanes 2-4 – Wild-type DNA.  Lanes 5-7 – Blank DNA.
Lanes 8-10 – G1138A Mutant DNA.  Lane 11 – Primer N2 used to test the PCR reaction
mix.  Lane 12 – HiLo Ladder.
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Figure 28.  Agarose gel of the test run with the allele specific wild-type and mutant primers
at 59°C using ½ the amount of template DNA.  Lane 1 – HiLo Ladder.  Lanes 2-4 – Wild-
type DNA.  Lanes 5-7 – Blank DNA.  Lanes 8-10 – G1138A Mutant DNA.  Lane 11 –
Primer N2 used to test the PCR reaction mix.
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Table 18.  Primer sequences and sizes for the allele specific PCR technique at site 1138.
The underscored bases correspond to site 1138.  The bolded ‘G’ represents a mismatch
incorporated to decrease the likelihood of false positives.
Primer Sequence (5’-3’) Size (bp)
asWtG2G1138 CAGGCATCCTCAGCCAGG 18
asMtA2G1138 CAGGCATCCTCAGCCAGA 18
type DNA.  The MtA2 primer did also make product with the G1138A mutant DNA
template, however, it was not known if this was a false positive because of the results with
the asMtA2 primer.  The negative results of the various allele specific assays resulted in
the termination of using allele specific PCR as a technique to determine the frequency of
achondroplasia mutations in populations of sperm.
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Figure 29.   Agarose gel of the test run with second set of the allele specific wild-type and
mutant primers.  Lane 1 – HiLo Ladder.  Lanes 2-3 – Wild-type DNA.  Lanes 4-5 – Blank
DNA.  Lanes 6-7 – G1138A Mutant DNA.  Lane 8 – HiLo Ladder.
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CHAPTER 10.  DISCUSSION
The development of a technique to measure the frequency of mutations in human
gametes would prove very valuable to aid in understanding the processes that lead to
inherited diseases.  Two such inherited mutations that lead to disease are the G1138A/C
and the C1620G/A FGFR-3 mutations.  These two single base site mutations are the cause
of achondroplasia and hypochondroplasia, respectively.
In an affected individual with either one or these diseases, the mutation occurs only
on the paternal allele.  In most situations, there is a de novo mutation because the father is
not usually affected with the disease.  Therefore, the mutation occurs spontaneously
somewhere in the paternal germline prior to or during spermatogenesis.  It is not known,
however, if the mutation occurs from a single rogue sperm carrying the mutation or from a
population of germ cells that are propagating the mutation.  Knowing how many sperm
cells carry one of the above mutations in the father of an affected individual would be very
beneficial in understanding the occurrence and multiplication of germline mutations.
Previous research has demonstrated enormous sensitivity and specificity of the
Needle-in-a-Haystack PCR/RE/LCR technique for single base mutations.  This research
has shown the technique to be capable of detecting not only a single base mutation in one
cell in a large population of cells, but also the exact type of base mutation.  By PCR
amplification followed by restriction endonuclease digestion of wild-type DNA, mutations
within a given area can be amplified while the amount of wild-type DNA can be reduced.
The reliability of this mutant selection and detection process has been well documented
(Wilson et al. 1999, 2000, 2001; Cerutti et al. 1994).
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This project focused on developing an assay for measuring the frequency of
achondroplasia and hypochondroplasia causing mutations in a large background of normal
cells.  PCR primers were developed to amplify the region around bases 1138 and 1620 of
the FGFR-3 gene to amplify the G1138A/C and the C1620A/G mutations causing
achondroplasia and hypochondroplasia, respectively.  The 1138 PCR primers were
designed to incorporate a BsaJI restriction site because a naturally occurring restriction
enzyme did not exist which would digest the wild-type DNA and select for the mutant
DNA.
Site 1620 provided many set backs from the beginning of the project.  After
numerous attempts to achieve sufficient digestion with the original restriction enzyme
BspMI failed, new PCR primers were designed to incorporate the restriction enzyme MspI.
The incorporation of this new sequence for the digestion of wild-type DNA with MspI was
successful in obtaining sufficient digestion in order to proceed on to the LCR section of the
assay.
The LCR technique for site 1620 showed limited success.  The wild-type primers
worked very well with both wild-type DNA and heterozygous mutant C1620A/G DNA.
The mutant primers also worked very well with larger amounts of mutant template DNA.
However, the mutant primers MtG and MtA were never able to successfully ligate with
oligonucleotide standard templates for the mutations.  The mutant primer MtT was,
however, able to ligate with the oligonucleotide mutant T standard, but the C1620T
mutation is not a proven naturally occurring mutation.  The MtT primers also showed a
zeal for product formation with almost any template at lower temperatures of the LCR
reactions, thereby producing false positives.
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Low sensitivities were obtained for both the C1620G and the C1620A mutations.
These sensitivities, though, were only on the order of about 1 mutant cell in a population of
100 wild-type cells.  This level of sensitivity is not adequate for the use of determining the
frequency of these disease causing mutations in human sperm.  This is because the
mutations in the human population occur at a much lower level per live birth, something
more on the level of achondroplasia which is about 1 in 15,000 to 1 in 40,000 live births.
The reasons behind failure of this approach to obtain adequate levels of sensitivity
could be placed at many different levels.  There may have been a problem with the actual
selection process.  Even though the PCR and RE reactions worked in the testing period,
there is no way to prove the actual selection process worked.  The difference between the
amount of DNA used in each PCR and the number of PCR cycles the DNA was subjected
to would be the two main reasons that the PCR/RE worked in the testing period and not in
the selection process.  For testing, 200 ng of DNA was subjected to about 120 total cycles
of PCR amplification, while during the selection process, as little as 0.006 ng of DNA was
subjected to only 65 cycles of PCR amplification.  Also, the addition of increasing levels
of primer and enzyme to the subsequent selection reactions might have caused interference
with the final LCR, i.e. primer/dimer combinations, competitive inhibition, and
mismatching.  This is an unlikely scenario, though, because it was shown that pure DNA
showed little more advantage for the LCR reaction than did DNA with reaction remnants.
More likely, the problems arose from limited specificity of the LCR primers
themselves and the combinations in which they were used.  The proper procedures were
followed in the original design process to develop primers that would work well together
and with the template DNA.  However, predicting how well the reagents will actually work
is sometimes a blind process.  The only way to properly assure the right combinations is to
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empirically test all of the primers against each other.  However, this is a very time
consuming and costly process.  Slight modifications to the designed primers and the
reaction properties are the only rational approaches to improving the techniques.  All of
these steps were followed, but to no avail.
The final consideration for failure of this technique is the region of the genome in
which the work was focused.  Through some, as yet unknown process, these sites on the
FGFR-3 gene might be refractory or inaccessible to modern conventional molecular
genetic techniques.  These sites, once mutated, might form sequences which make it very
hard for the enzymes used in the assay to work efficiently.
The mutation at site 1138 also provided many complications with previous work in
the lab (Wilson et. Al, unpublished data).  As with site 1620, the PCR/RE selection process
was believed to be working properly, however, the LCR detection process never reached
adequate levels of detection sensitivity.  Because achondroplasia is such an important and
prominent human genetic disease, new techniques were developed to try and reach the
desired sensitivities at this site before attempting to reach the desired sensitivities at the
hypochondroplasia mutation site 1620.
Allele specific PCR primers were then designed to detect the type of mutation at
site 1138.  This process would use the same PCR/RE selection process but use allele
specific PCR for the detection process.  These primers, however, primed nonspecifically to
all template types, regardless of the mutations.  Redesigned primers also failed to bind
precisely to the correct template.
The reasons for failure at this site fall along the same lines as for the failure for site
1620.  The selection process, the LCR primer combinations, and the region of the genome
are all valid complications that might have occurred during the refinement of this
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technique.  The problems observed in the attempts for the molecular analysis of these
FGFR-3 mutations may also represent clues as to why these single base mutations are
prominent disease causing problems in the human population.  The G1138A/C and the
C1620G/A mutations might be naturally resistant to normal cellular repair and correction
systems.  This study might also argue the belief that the Needle-in-a-Haystack approach to
studying low frequencies of mutated nucleotides in a large background of wild-type cells
might not in fact be a universal technique.
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CHAPTER 11.  CONCLUSIONS
Future attempts at obtaining high sensitivities of detection of achondroplasia and
hypochondroplasia causing mutations should not be deterred because of these failures.
Progress has recently been achieved at site 1138 in the lab of Baker et al. (2000).  They
have recently reported that through their technique, they found the frequency of the
achondroplasia causing mutation in the sperm of one sample (sperm of a man with an
achondroplastic child) to be on the order of about 1 mutated sperm per 22,000 wild type
sperm.  Their method of determining the frequency was by using the Invader Operation
System.  However, this reported frequency is shaky at best due to the limitations of the
Invader assay.
The Invader system is an isothermal, homogenous genotyping assay that uses
fluorescence energy transfer as a detection method.  The specificity of the Invader
Operation System is believed to be able to discriminate mutant and wild-type alleles at a
resolution of at least 1:1000.  It should also be noted that the high end level of sensitivity
of this assay is on the same level as the reported frequency of the mutation.  Because there
is not a very wide margin of error at this level of sensitivity, the validity of the mutation
frequency occurring at 1 in 12,000 is difficult to believe with total certainty.
The interesting point behind this study, if it is indeed valid, is that the frequency of
the mutation in this man’s sperm falls along one of the low end estimates of the frequency
of achondroplastic live births in the population, about 1 in 15,000.  If this proves to be true,
there may be no prenatal selection against the mutation, i.e. it does not come from a
germline event from the father.  It may in fact be a mutation in the sperm after maturation
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that leads to disease.  However, this does not explain the increased frequency of
achondroplasia with increasing age of the father.
The ability to determine the frequency of paternal inherited diseases derived from
germline mutations in a population of sperm is a very valuable tool.  With such an assay,
the frequency of the disease causing mutations could be determined in the germ cells of the
father of an affected individual.  Finally, the background of the mutation in the normal
population could be determined.  With all of these factors known about a given inherited
disease, the picture clears and many theories can be applied from it to other sex specific
inherited diseases.  With this approach, environmental exposures and other exposures to
toxic compounds could be evaluated for producing these mutations.  It might also be
determined that fathers of an affected child were previously exposed to a toxic mutagenic
agent(s).
The study of germline mutations is a very important resource for discovering the
reasons behind inherited mutations.  The two diseases, achondroplasia and
hypochondroplasia provide excellent models for determining sex specific germline
mutation processes and how they impact second and third generations.  Future endeavors
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